Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

Regenerage International, IIMET, and Bioquark Inc. to Collaborate on Clinical Study in Biologic Age Reversal of Photodamaged Skin

Regenerage, IIMET, and Bioquark, Inc. are undertaking a 12-week clinical trial, of a novel topical formulation, to study biologic reversal of aging in photodamaged skin.


News provided by

Bioquark Inc.

Jul 18, 2019, 17:00 ET

Share this article

Share toX

Share this article

Share toX


CHICAGO, PHILADELPHIA, and ZAPOPAN, Mexico, July 18, 2019 /PRNewswire-PRWeb/ -- Regenerage International Inc., a clinical company focused on therapeutic and consumer applications of regenerative healthcare; IIMET, a Mexico based contract research organization (CRO); and Bioquark, Inc., a life sciences company focused on the development of novel combinatorial bioproducts for regeneration and disease reversion, have announced a 12-week, placebo controlled, human clinical trial to study the biologic age-reversal properties of a twice daily application, of a novel topical formulation (RGR-003) in 10 subjects with photodamaged skin.

"We are very excited about this upcoming study of RGR-003," said Dr. Joel Osorio, Founder of Regenerage. "In 2019, the ability to study multiple levels of skin biodynamics in human subjects, at the tissue structure, cellular, biomolecular, and genetic levels, opens up new possibilities to understand and intervene in various dermatological conditions, including biologic aging."

“This study is another step forward for us in validating our strategy of creating combinatorial bioproducts that can both reprogram and remodel human tissues for comprehensive regeneration and rejuvenation purposes”, said Ira Pastor, CEO of Bioquark Inc.

Post this

Skin represents the largest organ in the human body, containing miles of vasculature and nerves, billions of pores and corpuscles, complex 3D architecture, and undertakes multifaceted biochemical, biomechanical, and bioelectric signaling with all organ systems encased within.
"Biologic aging" refers to the integrated negative changes that occur across these systems and represent the core drivers of downstream disease and degeneration.

Skin disorders, including cancers, autoimmune diseases, inflammatory conditions, and allergies, represent hundreds of billions of dollars annually, globally, in direct and indirect costs, and all have biologic aging processes as core drivers to their progression. Recent studies in the peer reviewed scientific literature are even beginning to connect skin damage, genetic changes and related "inflamm-aging" signaling factors to a wide variety of chronic diseases throughout the body's organ systems, including Alzheimer's, Heart Disease and Diabetes.

"We look forward to working closely with Regenerage and Bioquark on this exciting initiative," said Dr Geannyne Villegas Rivera, IIMET Principal Investigator. "The ability to combine our novel testing resources, with their novel biologic approaches, offers the opportunity to look deeper at disease transitions and effect beneficial changes in human pathology, including aging, as opposed to just effecting symptoms of conditions."

The ability to turn back biologic age, in a controlled manner, across various tissues, organs, and body segments, is a ubiquitous process found in many species in the animal kingdom, including many fish, amphibians, and invertebrates. Those organisms capable of this age reversal, possess the inherent ability to re-establish both the embryogenic potential of their genomes and the step-wise morphodynamic remodeling of their tissues.

"This study is another step forward for us in validating our strategy of creating combinatorial bioproducts, such as RGR-003, that can both reprogram and remodel human tissues in-vivo, for comprehensive regeneration and rejuvenation purposes", said Ira Pastor, CEO of Bioquark Inc.

About Regenerage International Inc.

Regenerage International is a novel clinical company focused on translational therapeutic applications of regenerative medicines, as well as developing consumer wellness and therapeutic skin care products - (http://regeneragebeauty.com/)

About IIMET

IIMET (Centro de Investigacion e Innovacion en Medicina Traslacional) is a Mexico based CRO focused on clinical research with a translational approach. It specializes in protocols with innovative products that contribute to improving the quality of life of their patients. It is made up of a multidisciplinary team of doctors and health personnel with extensive experience in clinical research protocols. Instituto Jalisciense De Investigacion Clinica S.A. de C.V. serves as the IIMET independent review board – (http://www.ijicsa.com/)

About Bioquark, Inc.

Bioquark Inc. is a novel life sciences company focused on the development of natural biologic based products, services, and technologies, with the goal of curing a wide range of diseases, as well as effecting complex regeneration - (http://www.bioquark.com)

SOURCE Bioquark Inc.

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.